NCT04906889

Brief Summary

The aim of this study is to investigate the effect of opioid-free anesthesia using dexmedetomidine and lidocaine instead of remifentanil infusion, on the acute postoperative pain after the gynecological laparoscopy

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2021

Geographic Reach
1 country

2 active sites

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 25, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 28, 2021

Completed
4 days until next milestone

Study Start

First participant enrolled

June 1, 2021

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2022

Completed
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2022

Completed
Last Updated

January 12, 2023

Status Verified

January 1, 2023

Enrollment Period

12 months

First QC Date

May 25, 2021

Last Update Submit

January 10, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • postoperative pain in recovery room

    The pain level is assessed by using NRS (numeric rating scale; 0=no pain , 10=the worst pain)

    30 minuetes after the completion of surgery

Secondary Outcomes (2)

  • shivering in recovery room

    30 minuetes after the completion of surgery

  • postoperative nausea and vomiting (PONV)

    30 minutes after the completion of surgery

Study Arms (2)

dexmedetomidine-lidocaine

EXPERIMENTAL

The study group receives the dexmedetomidine and lidocaine infusion with general anesthesia for gynecological laparoscopy.

Drug: Dexmedetomidine HydrochlorideDrug: Lidocaine Hydrochloride

remifentanil

ACTIVE COMPARATOR

The control group receives the remifentanil infusion with general anesthesia for gynecological laparoscopy

Drug: Remifentanil Hydrochloride

Interventions

dexmedetomidine iv bolus for 10 minutes followed by the infusion of 0.1-1 ug/kg/h during general anesthesia

Also known as: precedex
dexmedetomidine-lidocaine

remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia

Also known as: remifentanil
remifentanil

lidocaine iv bolus followed by the infusion of 1.5mg/kg/h during general anesthesia

Also known as: lidocaine
dexmedetomidine-lidocaine

Eligibility Criteria

Age20 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients scheduled for elective gynecological laparoscopy

You may not qualify if:

  • emergent surgery
  • cancer surgery
  • chronic pain requiring pain killers
  • psychiatric disease
  • preoperative bradycardia (HR \< 50 bpm)
  • allergies
  • pregnancy or breast feeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Seoul St.Mary's Hospital

Seoul, Seocho-gu, 06591, South Korea

Location

Seoul St.Mary's Hospital

Seocho, 06591, South Korea

Location

MeSH Terms

Conditions

Genital Diseases, Female

Interventions

DexmedetomidineRemifentanilLidocaine

Condition Hierarchy (Ancestors)

Female Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPropionatesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsPiperidinesAcetanilidesAnilidesAmidesAniline CompoundsAmines

Study Officials

  • Young Eun Moon, MD, PhD

    Associate professor, Department of Anesthesiology and Pain Medicine

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor

Study Record Dates

First Submitted

May 25, 2021

First Posted

May 28, 2021

Study Start

June 1, 2021

Primary Completion

May 30, 2022

Study Completion

June 1, 2022

Last Updated

January 12, 2023

Record last verified: 2023-01

Data Sharing

IPD Sharing
Will not share

Locations